Quantitative p24 antigenaemia for monitoring response to antiretroviral therapy in HIV-1 group O-infected patients

Antiviral Therapy

Volumn 3, Issue 3, 1998, Pages 187-189

  Soriano, Vincent ^a  

^a NONE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGEN P24; ANTIRETROVIRUS AGENT; DIDANOSINE; INDINAVIR; LAMIVUDINE; RITONAVIR; SAQUINAVIR; STAVUDINE; ZIDOVUDINE;

ADOLESCENT; ADULT; ARTICLE; BLOOD SAMPLING; CLINICAL FEATURE; DISEASE MARKER; DRUG RESPONSE; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPHOCYTE COUNT; MALE; PRIORITY JOURNAL; TREATMENT OUTCOME; VIRUS LOAD; VIRUS TYPING;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ADOLESCENT; ADULT; ANTI-HIV AGENTS; CD4 LYMPHOCYTE COUNT; FEMALE; HIV CORE PROTEIN P24; HIV-1; HUMANS; MALE; MIDDLE AGED;

EID: 17344367030     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (13)

1. Myers G, Korber B & Berzofsky J. Compilation and analysis of nucleic acid and amino acid sequences. Theoretical Biology and Biophysics Group T-10; 1996 Los Alamos: New Mexico, Los Alamos National Laboratory.
2. Loussert-Ajaka I, Ly T & Chaix M. HIV-1/HIV-2 seronega tivity in HIV-1 subtype O infected patients. Lancet 1994; 343:1393-1394.
3. Gürtler L, Zekeng L & Simon F. Reactivity of five anti-HIV-1 subtype O specimens with different anti-HIV screening ELISAs and three immunoblots. Journal of Virological Methods 1995; 51:177-184.
4. Clewley JP. Genetic diversity and HIV detection by PCR. Lancet 1995; 346:1489.
5. Loussert-Ajaka I, Descamps D, Simon F, Brun-Vézinet F, Ekwalanga M & Saragosti S. Genetic diversity and HIV detection by polymerase chain reaction. Lancet 1995; 346:912-913.
6. Soriano V, Gómez-Cano M, Bravo R, Mas A, Villalba N, Holguín A, González-Lahoz J & Castilla J. Comparison of three different commercial methods for quantification of plasma HIV RNA in clinical specimens. Antiviral Therapy 1997; 2:119-120.
7. Descamps D, Collin G, Loussert-Ajaka I, Saragosti S, Simon F & Brun-Vézinet F. HIV-1 group O sensitivity to antiretroviral drugs. AIDS 1995; 9:977-978.
8. Soriano V, Gutierrez M & García-Lerma G, Aguilera O, Mas A, Bravo R, Pérez-Labad M, Baquero M & González-Lahoz J. First case of HIV-1 group O infection in Spain. Vox Sanguinis 1996; 71:66.
9. Mas A, Quiñones-Mateu M, Soriano V & Domingo E. Env gene characterization of the first HIV type 1 group O Spanish isolate. AIDS Research & Human Retroviruses 1996; 12:1647-1649.
10. Trabaud M, Audoly G & Leriche K. Development of a reverse-transcriptase PCR-enzyme-linked immunosorbent assay for quantification of HIV type 1 RNA in plasma: comparison with commercial quantitative assays. Journal of Clinical Microbiology 1997, 35:1251-1254.
11. Boni J, Opravil M & Tomasik Z. Simple monitoring of antiretroviral therapy with a signal-amplification boosted HIV-1 p24 antigen assay with heat-denatured plasma. AIDS 1997; 11:F47-F52.
12. Heneine W, Yamamoto S, Switzer W, Spira T & Folks T. Detection of reverse-transcriptase by a highly sensitive assay in sera from persons infected with HIV type 1. Journal of Infections Diseases 1995; 171:210-216.
13. García-Lerma G, Yamamoto S, Gomez-Cano M, Soriano V, Green T, Busch M, Folks T & Heneine W. Measurement of HIV type 1 plasma virus load based on reverse transcriptase (RT) activity: evidence of variabilities in levels of virion-associated RT. Journal of Infections Diseases 1998; 177:1221-1229